Literature DB >> 23838348

Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.

Cassandra C Deford1, Jessica A Reese, Lauren H Schwartz, Jedidiah J Perdue, Johanna A Kremer Hovinga, Bernhard Lämmle, Deirdra R Terrell, Sara K Vesely, James N George.   

Abstract

Recovery from acute episodes of thrombotic thrombocytopenic purpura (TTP) appears complete except for minor cognitive abnormalities and risk for relapse. The Oklahoma TTP-HUS (hemolytic uremic syndrome) Registry enrolled 70 consecutive patients from 1995 to 2011 with ADAMTS13 activity <10% at their initial episode; 57 survived, with follow-up through 2012. The prevalence of body mass index (BMI), glomerular filtration rate (GFR), urine albumin/creatinine ratio (ACR), hypertension, major depression, systemic lupus erythematosus (SLE), and risk of death were compared with expected values based on the US reference population. At initial diagnosis, 57 survivors had a median age of 39 years; 45 (79%) were women; 21 (37%) were black; BMI and prevalence of SLE (7%) were greater (P < .001) than expected; prevalence of hypertension (19%; P = .463) was not different. GFR (P = .397) and ACR (P = .793) were not different from expected values. In 2011-2012, prevalence of hypertension (40% vs 23%; P = .013) and major depression (19% vs 6%; P = .005) was greater than expected values. Eleven patients (19%) have died, a proportion greater than expected compared with US and Oklahoma reference populations (P < .05). TTP survivors may have greater risk for poor health and premature death.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23838348      PMCID: PMC3778546          DOI: 10.1182/blood-2013-04-496752

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

Review 1.  Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus.

Authors:  James N George; Sara K Vesely; Judith A James
Journal:  South Med J       Date:  2007-05       Impact factor: 0.954

2.  Survival and relapse in patients with thrombotic thrombocytopenic purpura.

Authors:  Johanna A Kremer Hovinga; Sara K Vesely; Deirdra R Terrell; Bernhard Lämmle; James N George
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

3.  Long-term, sub-clinical cardiac and renal complications in patients with multiple relapses of thrombotic thrombocytopenic purpura.

Authors:  Srividya Viswanathan; Brad H Rovin; Ganesh B Shidham; Subha V Raman; Mitchell Weinberg; Allenby Patricia; James N George; Haifeng M Wu; Spero R Cataland
Journal:  Br J Haematol       Date:  2010-02-09       Impact factor: 6.998

Review 4.  Assessment of mood: guides for clinicians.

Authors:  Toshi A Furukawa
Journal:  J Psychosom Res       Date:  2009-07-10       Impact factor: 3.006

Review 5.  Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies.

Authors:  Floriana S Luppino; Leonore M de Wit; Paul F Bouvy; Theo Stijnen; Pim Cuijpers; Brenda W J H Penninx; Frans G Zitman
Journal:  Arch Gen Psychiatry       Date:  2010-03

6.  Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura.

Authors:  Qurana F Lewis; Marion S Lanneau; Susan D Mathias; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Transfusion       Date:  2008-10-02       Impact factor: 3.157

Review 7.  Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review.

Authors:  Beau M Hawkins; Mazen Abu-Fadel; Sara K Vesely; James N George
Journal:  Transfusion       Date:  2007-11-19       Impact factor: 3.157

8.  Cognitive deficits after recovery from thrombotic thrombocytopenic purpura.

Authors:  April S Kennedy; Qurana F Lewis; James G Scott; Johanna A Kremer Hovinga; Bernhard Lämmle; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Transfusion       Date:  2009-02-13       Impact factor: 3.157

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies.

Authors:  Gary Whitlock; Sarah Lewington; Paul Sherliker; Robert Clarke; Jonathan Emberson; Jim Halsey; Nawab Qizilbash; Rory Collins; Richard Peto
Journal:  Lancet       Date:  2009-03-18       Impact factor: 79.321

View more
  54 in total

1.  Atypical presentations of thrombotic thrombocytopenic purpura: a diagnostic role for ADAMTS13.

Authors:  Yosef Kalish; Amihai Rottenstreich; Deborah Rund; Sarit Hochberg-Klein
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

Review 2.  TTP: long-term outcomes following recovery.

Authors:  James N George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Thrombotic microangiopathies: a general approach to diagnosis and management.

Authors:  Donald M Arnold; Christopher J Patriquin; Ishac Nazy
Journal:  CMAJ       Date:  2016-10-17       Impact factor: 8.262

4.  Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura.

Authors:  Bowie Han; Evaren E Page; Lauren M Stewart; Cassandra C Deford; James G Scott; Lauren H Schwartz; Jedidiah J Perdue; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Am J Hematol       Date:  2015-05-28       Impact factor: 10.047

5.  Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why?

Authors:  James N George
Journal:  Transfusion       Date:  2015-01       Impact factor: 3.157

6.  Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Evaren E Page; Johanna A Kremer Hovinga; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2016-09-13       Impact factor: 22.113

7.  Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.

Authors:  Evaren E Page; Johanna A Kremer Hovinga; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood Adv       Date:  2017-04-06

8.  Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.

Authors:  Jingrui Sui; Wenjing Cao; Konstantine Halkidis; Mohammad S Abdelgawwad; Nicole K Kocher; Bryan Guillory; Lance A Williams; Radhika Gangaraju; Marisa B Marques; X Long Zheng
Journal:  Blood Adv       Date:  2019-12-23

9.  Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura.

Authors:  Wenjing Cao; Huy P Pham; Lance A Williams; Jenny McDaniel; Rance C Siniard; Robin G Lorenz; Marisa B Marques; X Long Zheng
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

10.  Increased morbidity during long-term follow-up of survivors of thrombotic thrombocytopenic purpura.

Authors:  Shruti Chaturvedi; Hashim Abbas; Keith R McCrae
Journal:  Am J Hematol       Date:  2015-09-10       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.